Elucidating/VBG
Molecular/JJ
Interactions/NNS
of/IN
Natural/JJ
Inhibitors/NNS
with/IN
HPV-16/NN
E6/NN
Oncoprotein/NN
through/IN
Docking/JJ
Analysis/NN
./.
====================
Human/JJ
papillomavirus/NN
(/(
HPV/NN
)/)
infection/NN
is/VBZ
the/DT
leading/VBG
cause/VBP
of/IN
cancer/NN
mortality/NN
among/IN
women/NNS
worldwide/NN
./.
====================
The/DT
life-threatening/JJ
infection/NN
caused/VBD
by/IN
HPV/NN
demands/VBZ
the/DT
need/NN
for/IN
designing/VBG
anticancerous/JJ
drugs/NNS
./.
====================
In/IN
the/DT
recent/JJ
years/NNS
,/,
different/JJ
compounds/NNS
from/IN
natural/JJ
origins/NNS
,/,
such/JJ
as/IN
carrageenan/JJ
,/,
curcumin/NN
,/,
epigallocatechin/NN
gallate/NN
,/,
indole-3-carbinol/NN
,/,
jaceosidin/NN
,/,
and/CC
withaferin/IN
,/,
have/VBP
been/VBN
used/VBN
as/IN
a/DT
hopeful/JJ
source/NN
of/IN
anticancer/JJ
therapy/NN
./.
====================
These/DT
compounds/NNS
have/VBP
been/VBN
shown/VBN
to/TO
suppress/VB
HPV/NN
infection/NN
by/IN
different/JJ
researchers/NNS
./.
====================
In/IN
the/DT
present/JJ
study/NN
,/,
we/PRP
explored/VBD
these/DT
natural/JJ
inhibitors/NNS
against/IN
E6/NN
oncoprotein/NN
of/IN
high-risk/JJ
HPV-16/NN
,/,
which/WDT
is/VBZ
known/VBN
to/TO
inactivate/VB
the/DT
p53/NN
tumor/NN
suppressor/NN
protein/NN
./.
====================
A/DT
robust/JJ
homology/NN
model/NN
of/IN
HPV-16/NN
E6/NN
was/VBD
built/JJ
to/TO
anticipate/JJ
the/DT
interaction/NN
mechanism/NN
of/IN
E6/NN
oncoprotein/NN
with/IN
natural/JJ
inhibitory/JJ
molecules/NNS
using/VBG
a/DT
structure-based/JJ
drug/NN
designing/VBG
approach/NN
./.
====================
Docking/VBG
analysis/NN
showed/VBD
the/DT
interaction/NN
of/IN
these/DT
natural/JJ
compounds/NNS
with/IN
the/DT
p53-binding/JJ
site/NN
of/IN
E6/NN
protein/NN
residues/NNS
113-122/CD
(/(
CQKPLCPEEK/NN
)/)
and/CC
helped/VBD
the/DT
restoration/NN
of/IN
p53/NN
functioning/VBG
./.
====================
Docking/VBG
analysis/NN
,/,
besides/VBZ
helping/VBG
in/IN
silico/NN
validation/NN
of/IN
natural/JJ
compounds/NNS
,/,
also/RB
helps/VBZ
understand/VB
molecular/JJ
mechanisms/NNS
of/IN
protein-ligand/NN
interactions/NNS
./.
====================
Human/JJ
papillomavirus/NN
(/(
HPV/NN
)/)
,/,
a/DT
virus/NN
from/IN
the/DT
papillomavirus/NN
family/NN
,/,
accounts/VBZ
for/IN
5.2/CD
%/NN
of/IN
all/DT
cancers/NNS
worldwide/NN
and/CC
is/VBZ
also/RB
the/DT
causative/JJ
agent/NN
of/IN
a/DT
subset/NN
of/IN
anogenital/JJ
,/,
head/RB
and/CC
neck/NN
cancers/NNS
,/,
and/CC
cervical/JJ
cancer/NN
[/(
1/CD
,/,
2/CD
]/)
./.
====================
Amongst/IN
these/DT
,/,
cervical/JJ
cancer/NN
contributes/VBZ
the/DT
most/JJS
to/TO
cancer/NN
mortality/NN
in/IN
women/NNS
worldwide/NN
,/,
with/IN
an/DT
estimated/VBN
49,300/CD
diagnoses/NNS
and/CC
274,000/CD
deaths/NNS
annually/RB
[/(
3/CD
]/)
./.
====================
Although/IN
there/EX
are/VBP
more/RBR
than/IN
200/CD
types/NNS
of/IN
HPV/NN
identified/VBN
,/,
the/DT
most/JJS
commonly/RB
associated/VBN
with/IN
cervical/JJ
cancer/NN
are/VBP
'high-risk/JJ
'/``
HPV-16/NN
and/CC
HPV-18/CD
,/,
responsible/JJ
for/IN
about/RB
62.6/CD
%/NN
and/CC
15.7/CD
%/NN
of/IN
cervical/JJ
cancers/NNS
,/,
respectively/RB
[/(
4/CD
]/)
./.
====================
Besides/RB
,/,
among/IN
all/DT
the/DT
HPV-associated/JJ
cancers/NNS
,/,
the/DT
proportion/NN
attributable/JJ
to/TO
HPV/NN
types/NNS
16/CD
and/CC
18/CD
is/VBZ
63-80/CD
%/NN
of/IN
penile/JJ
cancers/NNS
,/,
80-86/CD
%/NN
of/IN
vulva/vaginal/JJ
cancers/NNS
,/,
93/CD
%/NN
of/IN
anal/JJ
cancers/NNS
,/,
and/CC
89-95/CD
%/NN
of/IN
oropharyngeal/JJ
cancers/NNS
[/(
5/CD
]/)
./.
====================
HPV-16/CD
and/CC
HPV-18/CD
remain/VBP
the/DT
primary/JJ
targets/NNS
for/IN
anticancer/JJ
drug/NN
development/NN
./.
====================
The/DT
E6/NN
and/CC
E7/NN
onco-proteins/NNS
have/VBP
been/VBN
shown/VBN
to/TO
interact/VB
specifically/RB
with/IN
the/DT
p53/NN
and/CC
pRb/NN
tumor/NN
suppressor/NN
proteins/NNS
,/,
respectively/RB
[/(
6/CD
]/)
./.
====================
Both/DT
pRb/NN
and/CC
p53/NN
negatively/RB
regulate/VB
the/DT
cell/NN
cycle/NN
and/CC
also/RB
appear/VBP
to/TO
inhibit/VB
G0-G1/NN
and/CC
G1-S/NN
phase/NN
transitions/NNS
./.
====================
These/DT
interactions/NNS
apparently/RB
play/VBP
important/JJ
roles/NNS
in/IN
the/DT
induction/NN
of/IN
cell/NN
immortality/NN
./.
====================
The/DT
importance/NN
of/IN
p53-mediated/JJ
apoptosis/NN
has/VBZ
been/VBN
recognized/VBN
in/IN
terms/NNS
of/IN
the/DT
maintenance/NN
of/IN
homeostasis/NN
,/,
as/IN
well/RB
as/IN
the/DT
prevention/NN
of/IN
neoplastic/JJ
transformation/NN
./.
====================
E6/CD
forms/NNS
a/DT
ternary/JJ
complex/NN
with/IN
p53/NN
and/CC
E6AP/NN
(/(
E6/CD
associated/VBN
protein/NN
)/)
,/,
resulting/VBG
in/IN
the/DT
degradation/NN
of/IN
p53/NN
via/IN
the/DT
ubiquitination/NN
pathway/NN
[/(
7/CD
]/)
./.
====================
HPV/NN
has/VBZ
been/VBN
known/VBN
as/IN
a/DT
causative/JJ
agent/NN
for/IN
cervical/JJ
cancer/NN
for/IN
3/CD
decades/NNS
,/,
but/CC
effective/JJ
treatment/NN
against/IN
HPV/NN
infection/NN
is/VBZ
still/RB
unavailable/JJ
[/(
8/CD
]/)
./.
====================
Natural/JJ
products/NNS
have/VBP
been/VBN
identified/VBN
as/IN
promising/JJ
sources/NNS
of/IN
drugs/NNS
for/IN
treatment/NN
and/CC
prevention/NN
of/IN
cancer/NN
in/IN
recent/JJ
years/NNS
[/(
9/CD
]/)
./.
====================
Carrageenan/NN
is/VBZ
known/VBN
to/TO
prevent/VB
the/DT
binding/NN
of/IN
HPV/NN
virions/NNS
to/TO
cells/NNS
./.
====================
It/PRP
can/MD
also/RB
block/VBP
HPV/NN
infection/NN
through/IN
a/DT
second/JJ
,/,
post/RB
attachment/NN
heparan/NN
sulfate-independent/JJ
effect/NN
[/(
10/CD
]/)
./.
====================
Bava/NN
et/FW
al/JJ
./.
====================
[/(
11/CD
]/)
demonstrated/VBD
that/IN
curcumin/NN
sensitizes/VBZ
cervical/JJ
cancer/NN
cells/NNS
to/TO
the/DT
therapeutic/JJ
effect/NN
of/IN
taxol/NN
,/,
acting/VBG
in/IN
the/DT
down-regulation/NN
of/IN
both/DT
nuclear/JJ
factor/NN
κB/NN
(/(
NF-κB/NN
)/)
and/CC
the/DT
threonine/serine/NN
kinase/NN
AKT/NN
pathway/NN
./.
====================
Curcumin/NN
is/VBZ
cytotoxic/JJ
to/TO
cervical/JJ
cancer/NN
cells/NNS
in/IN
a/DT
concentration-dependent/JJ
and/CC
time-dependent/JJ
manner/NN
,/,
and/CC
the/DT
cytotoxicity/NN
is/VBZ
higher/JJR
in/IN
HPV-infected/JJ
cells/NNS
./.
====================
The/DT
authors/NNS
confirmed/VBD
the/DT
inhibitory/JJ
action/NN
of/IN
curcumin/NN
on/IN
NF-κB/NN
activation/NN
,/,
through/IN
the/DT
degradation/NN
of/IN
IκB/NN
,/,
and/CC
on/IN
AP-1/NN
binding/NN
,/,
which/WDT
results/VBZ
in/IN
the/DT
downregulation/NN
of/IN
cyclooxygenase/NN
2/CD
(/(
COX-2/NN
)/)
and/CC
increased/VBD
tumor/NN
cell/NN
apoptosis/NN
[/(
11/CD
]/)
./.
====================
Moreover/RB
,/,
it/PRP
was/VBD
shown/VBN
that/IN
curcumin/NN
downregulates/VBZ
the/DT
expression/NN
of/IN
E6/NN
and/CC
E7/NN
proteins/NNS
of/IN
HPV-16/NN
,/,
resulting/VBG
in/IN
loss/NN
of/IN
the/DT
transforming/VBG
phenotype/NN
and/CC
the/DT
cessation/NN
of/IN
cellular/JJ
growth/NN
./.
====================
Singh/IN
and/CC
Singh/JJ
[/(
12/CD
]/)
explored/VBD
other/JJ
molecular/JJ
mechanisms/NNS
exerted/VBD
by/IN
curcumin/NN
in/IN
cervical/JJ
cancer/NN
cells/NNS
,/,
showing/VBG
that/IN
it/PRP
inhibits/VBZ
telomerase/NN
activity/NN
,/,
the/DT
RAS/NN
and/CC
ERK/NN
signaling/VBG
pathway/NN
,/,
cyclin/NN
D1/NN
,/,
COX-2/NN
,/,
and/CC
inducible/JJ
nitric/JJ
oxide/NN
synthase/NN
activity/NN
./.
====================
Withaferin/IN
A/DT
(/(
WA/NN
)/)
is/VBZ
the/DT
major/JJ
active/JJ
component/NN
of/IN
the/DT
Indian/JJ
medicinal/JJ
plant/JJ
Withania/NN
somnifera/RB
,/,
with/IN
antitumor/JJ
,/,
antiangiogenic/JJ
,/,
and/CC
radiosensitizing/JJ
activity/NN
[/(
13/CD
,/,
14/CD
]/)
./.
====================
An/DT
in/IN
vitro/FW
and/CC
in/IN
vivo/FW
study/NN
conducted/VBD
by/IN
Munagala/NN
et/FW
al/JJ
./.
====================
[/(
15/CD
]/)
showed/VBD
the/DT
inhibitory/JJ
effect/NN
of/IN
WA/NN
against/IN
the/DT
proliferation/NN
of/IN
cervical/JJ
cancer/NN
cells/NNS
./.
====================
WA/NN
was/VBD
shown/VBN
to/TO
downregulate/VB
the/DT
expression/NN
of/IN
HPV/NN
E6/NN
oncoprotein/NN
and/CC
restore/VB
the/DT
p53/NN
pathway/NN
,/,
resulting/VBG
in/IN
apoptosis/NN
of/IN
cervical/JJ
cancer/NN
cells/NNS
[/(
15/CD
]/)
./.
====================
(/(
-/:
)/)
-Epigallocatechin-3-gallate/JJ
(/(
EGCG/NN
)/)
,/,
the/DT
most/JJS
abundant/JJ
and/CC
active/JJ
tea/NN
catechin/NN
,/,
has/VBZ
antiviral/JJ
and/CC
antitumor/JJ
properties/NNS
./.
====================
According/VBG
to/TO
a/DT
clinical/JJ
study/NN
,/,
EGCG/NN
was/VBD
effective/JJ
in/IN
patients/NNS
with/IN
HPV-infected/JJ
cervical/JJ
lesions/NNS
when/WRB
delivered/VBN
in/IN
the/DT
form/NN
of/IN
ointment/JJ
or/CC
capsule/NN
[/(
16/CD
]/)
./.
====================
A/DT
study/NN
conducted/VBD
by/IN
Qiao/NN
et/FW
al/JJ
./.
====================
[/(
17/CD
]/)
showed/VBD
the/DT
inhibition/NN
effect/NN
of/IN
EGCG/NN
on/IN
the/DT
growth/NN
of/IN
CaSki/NN
(/(
HPV-16/NN
positive/JJ
)/)
and/CC
HeLa/NN
(/(
HPV-18/CD
positive/JJ
)/)
cells/NNS
in/IN
a/DT
time-/NN
and/CC
concentration-dependent/JJ
manner/NN
./.
====================
Their/PRP$
results/NNS
also/RB
observed/VBN
that/IN
EGCG/NN
could/MD
inhibit/VB
the/DT
expression/NN
of/IN
HPV/NN
E6/E7/NN
./.
====================
Lee/NNP
et/FW
al/JJ
./.
====================
[/(
18/CD
]/)
isolated/VBN
jaceosidin/NN
from/IN
the/DT
methanol/NN
(/(
MeOH/NN
)/)
extract/NN
of/IN
Artemisia/NN
argyi/NN
and/CC
reported/VBD
its/PRP$
inhibitory/JJ
effects/NNS
on/IN
binding/NN
between/IN
oncoproteins/NNS
and/CC
tumor/NN
suppressor/NN
p53/NN
./.
====================
Indole-3-carbinol/RB
(/(
I3C/NN
)/)
,/,
found/VBN
in/IN
cruciferous/JJ
vegetables/NNS
,/,
such/JJ
as/IN
cauliflower/JJR
,/,
broccoli/FW
,/,
cabbage/JJ
,/,
and/CC
brussel/NN
sprouts/NNS
,/,
was/VBD
demonstrated/VBN
to/TO
have/VB
anti-estrogenic/JJ
activities/NNS
in/IN
cervical/JJ
cells/NNS
[/(
19/CD
]/)
./.
====================
The/DT
purpose/NN
of/IN
this/DT
in/IN
silico/NN
study/NN
was/VBD
to/TO
observe/VB
the/DT
interaction/NN
between/IN
active/JJ
compounds/NNS
obtained/VBN
from/IN
natural/JJ
products/NNS
used/VBN
for/IN
the/DT
treatment/NN
against/IN
HPV/NN
./.
====================
In/IN
this/DT
study/NN
,/,
a/DT
three-dimensional/JJ
structure/NN
of/IN
E6/NN
protein/NN
of/IN
HPV/NN
type/NN
16/CD
was/VBD
modeled/VBN
using/VBG
the/DT
Phyre/JJ
2/CD
server/RB
,/,
and/CC
structural/JJ
refinement/JJ
and/CC
energy/NN
minimization/NN
were/VBD
performed/VBN
by/IN
the/DT
YASARA/NN
Energy/NN
Minimization/NN
Server/NN
./.
====================
In/IN
order/NN
to/TO
reveal/VB
the/DT
interaction/NN
between/IN
E6/CD
oncoprotein/NN
with/IN
natural/JJ
ligands/NNS
,/,
docking/NN
analysis/NN
was/VBD
performed/VBN
using/VBG
the/DT
AutoDock/NN
tool/NN
./.
====================
Hardware/JJ
and/CC
software/JJ
====================
The/DT
study/NN
was/VBD
carried/VBN
out/RP
on/IN
a/DT
Dell/JJ
Workstation/NN
with/IN
a/DT
2.26/CD
GHz/NN
processor/NN
,/,
6/CD
GB/NN
RAM/NN
,/,
and/CC
500/CD
GB/NN
hard/VBP
drive/VBP
running/JJ
in/IN
the/DT
Windows/NNS
operating/VBG
system/NN
./.
====================
Bioinformatics/NNS
software/JJ
,/,
such/JJ
as/IN
AutoDock4.0/CD
and/CC
online/JJ
resources/VBZ
,/,
were/VBD
used/VBN
in/IN
this/DT
study/NN
./.
====================
E6/CD
of/IN
HPV-16/NN
====================
E6/CD
protein/NN
of/IN
HPV-16/NN
was/VBD
selected/VBN
as/IN
the/DT
drug/NN
target/NN
./.
====================
The/DT
HPV-16/NN
E6/NN
(/(
GenBank/NN
ID/NN
:/:
AAD33252.1/NN
)/)
protein/NN
sequence/NN
was/VBD
retrieved/VBN
from/IN
NCBI/NN
(/(
http/NN
:/:
//www.ncbi.nlm.nih.gov//JJ
)/)
./.
====================
Protein/NN
structure/NN
prediction/NN
and/CC
validation/NN
of/IN
drug/NN
target/NN
====================
For/IN
modeling/VBG
of/IN
the/DT
three-dimensional/JJ
structure/NN
of/IN
the/DT
E6/NN
protein/NN
,/,
Phyre/JJ
2/CD
server/RB
[/(
20/CD
]/)
was/VBD
used/VBN
./.
====================
Structural/JJ
refinement/JJ
and/CC
energy/NN
minimization/NN
of/IN
the/DT
predicted/VBN
model/NN
were/VBD
carried/VBN
out/RP
using/VBG
the/DT
YASARA/NN
Energy/NN
Minimization/NN
Server/NN
[/(
21/CD
]/)
./.
====================
The/DT
refined/VBN
model/NN
reliability/NN
was/VBD
assessed/VBN
through/IN
Procheck/NN
[/(
22/CD
]/)
,/,
ProSA-web/NN
[/(
23/CD
]/)
,/,
ProQ/NN
[/(
24/CD
]/)
,/,
and/CC
Verify-3D/NNP
[/(
25/CD
]/)
./.
====================
The/DT
refined/VBN
model/NN
was/VBD
further/RBR
verified/VBN
by/IN
the/DT
ERRAT/NN
server/RB
[/(
26/CD
]/)
./.
====================
Ligand/NN
preparation/NN
====================
Chemical/JJ
structures/NNS
of/IN
natural/JJ
compounds/NNS
(/(
carrageenan/NN
,/,
curcumin/NN
,/,
EGCG/NN
,/,
I3C/NN
,/,
jaceosidin/NN
,/,
WA/NN
)/)
,/,
along/IN
with/IN
CAS/NN
(/(
Chemical/JJ
Abstracts/NNS
Service/NN
)/)
registry/RB
numbers/NNS
,/,
reported/VBD
in/IN
the/DT
literature/NN
were/VBD
retrieved/VBN
from/IN
the/DT
PubChem/JJ
database/NN
(/(
Fig/NN
./.
====================
1/CD
)/)
[/(
27/CD
]/)
./.
====================
Protein-ligand/CC
docking/NN
====================
Protein-ligand/CC
docking/NN
studies/NNS
were/VBD
performed/VBN
using/VBG
the/DT
AutoDock/NN
4.2/CD
program/NN
[/(
28/CD
]/)
./.
====================
It/PRP
is/VBZ
one/CD
of/IN
the/DT
most/JJS
widely/RB
used/VBN
methods/NNS
for/IN
protein-ligand/NN
docking/NN
./.
====================
All/DT
the/DT
pre-processing/VBG
steps/NNS
for/IN
ligand/NN
and/CC
protein/NN
files/NNS
were/VBD
performed/VBN
using/VBG
AutoDock/NN
Tools/NNS
1.5.4/CD
(/(
ADT/NN
)/)
,/,
which/WDT
has/VBZ
been/VBN
released/VBN
as/IN
an/DT
extension/NN
suite/JJ
to/TO
the/DT
Python/NN
Molecular/JJ
Viewer/JJR
[/(
28/CD
]/)
./.
====================
ADT/NN
was/VBD
used/VBN
to/TO
prepare/VB
the/DT
receptor/NN
molecule/NN
(/(
HPV-16/NN
E6/NN
)/)
by/IN
adding/VBG
all/DT
hydrogen/NN
atoms/NNS
into/IN
carbon/JJ
atoms/NNS
of/IN
the/DT
receptor/NN
,/,
and/CC
Kollman/JJ
charges/NNS
were/VBD
also/RB
assigned/VBD
./.
====================
For/IN
docked/VBD
ligands/NNS
,/,
non-polar/JJ
hydrogens/NNS
were/VBD
also/RB
added/VBN
./.
====================
Gasteiger/RBR
charges/NNS
were/VBD
assigned/VBN
and/CC
torsions/NNS
degrees/NNS
of/IN
freedom/JJ
were/VBD
allocated/VBN
by/IN
ADT/NN
./.
====================
The/DT
Lamarckian/JJ
genetic/JJ
algorithm/NN
(/(
LGA/NN
)/)
was/VBD
applied/VBN
to/TO
model/VB
the/DT
interaction/NN
pattern/NN
between/IN
the/DT
E6/NN
oncogenic/JJ
protein/NN
and/CC
selected/VBN
inhibitors/NNS
./.
====================
The/DT
grid/JJ
maps/VBZ
representing/VBG
the/DT
receptor/NN
proteins/NNS
in/IN
the/DT
docking/NN
process/NN
were/VBD
calculated/VBN
using/VBG
AutoGrid/JJ
(/(
part/NN
of/IN
the/DT
AutoDock/NN
package/NN
)/)
./.
====================
A/DT
grid/JJ
of/IN
50/CD
,/,
50/CD
,/,
and/CC
50/CD
points/NNS
in/IN
the/DT
x/NN
,/,
y/RB
,/,
and/CC
z/NN
directions/NNS
was/VBD
centered/JJ
on/IN
the/DT
p53-binding/JJ
sites/NNS
of/IN
E6/NN
proteins/NNS
./.
====================
For/IN
all/DT
docking/NN
procedures/NNS
,/,
10/CD
independent/JJ
genetic/JJ
algorithm/NN
runs/NNS
with/IN
a/DT
population/NN
size/NN
of/IN
150/CD
were/VBD
considered/VBN
for/IN
each/DT
molecule/NN
under/IN
study/NN
./.
====================
A/DT
maximum/JJ
number/NN
of/IN
25/CD
×/NN
105/CD
energy/NN
evaluations/NNS
,/,
27,000/CD
maximum/NN
generations/NNS
,/,
a/DT
gene/NN
mutation/NN
rate/NN
of/IN
0.02/CD
,/,
and/CC
a/DT
crossover/JJ
rate/NN
of/IN
0.8/CD
were/VBD
used/VBN
for/IN
the/DT
LGA/NN
./.
====================
Autodock/NN
was/VBD
run/JJ
in/IN
order/NN
to/TO
prepare/VB
corresponding/VBG
docking/NN
log/NN
file/JJ
(/(
DLG/NN
)/)
files/NNS
for/IN
further/JJ
analysis/NN
./.
====================
Visualization/NN
====================
The/DT
visualization/NN
of/IN
structure/NN
files/NNS
was/VBD
done/VBN
using/VBG
the/DT
graphical/JJ
interface/NN
of/IN
the/DT
ADT/NN
tool/NN
and/CC
the/DT
PyMol/NN
molecular/JJ
graphics/NNS
system/NN
(/(
http/NN
:/:
//www.pymol.org/JJ
)/)
./.
====================
Tertiary/JJ
structure/NN
modeling/VBG
and/CC
validation/NN
====================
E6/CD
protein/NN
of/IN
HPV/NN
type/NN
16/CD
has/VBZ
158/CD
amino/NN
acids/NNS
in/IN
its/PRP$
protein/NN
sequence/NN
./.
====================
Since/IN
the/DT
three-dimensional/JJ
structure/NN
of/IN
E6/NN
was/VBD
not/RB
available/JJ
,/,
its/PRP$
structure/NN
model/NN
was/VBD
predicted/VBN
using/VBG
the/DT
Phyre/JJ
2/CD
server/RB
by/IN
taking/VBG
chain/NN
C/NN
of/IN
the/DT
crystal/JJ
structure/NN
of/IN
full-length/JJ
HPV/NN
oncoprotein/NN
e62/NN
in/IN
complex/NN
with/IN
the/DT
lxxll/JJ
peptide/NN
of/IN
ubiquitin/NN
ligase/NN
e6ap/RB
(/(
PDB/NN
ID/NN
:/:
4GIZ/CD
)/)
as/IN
a/DT
structural/JJ
template/NN
./.
====================
The/DT
query/RB
coverage/NN
of/IN
the/DT
target-template/NN
alignment/NN
was/VBD
90/CD
%/NN
with/IN
96/CD
%/NN
identity/NN
./.
====================
The/DT
predicted/VBN
structure/NN
was/VBD
then/RB
subjected/VBD
to/TO
the/DT
Yet/RB
Another/DT
Scientific/JJ
Artificial/JJ
Reality/NN
Application/NN
(/(
YASARA/NN
)/)
Energy/NN
Minimization/NN
Server/NN
for/IN
structural/JJ
refinement/JJ
./.
====================
The/DT
total/JJ
energy/NN
for/IN
the/DT
refined/VBN
structure/NN
obtained/VBN
from/IN
the/DT
YASARA/NN
Energy/NN
Minimization/NN
Server/NN
was/VBD
-48,054.9/CD
kcal/mol/NN
(/(
score/RB
,/,
-2.55/CD
)/)
,/,
whereas/IN
prior/JJ
to/TO
energy/NN
minimization/NN
,/,
it/PRP
was/VBD
81,463,636,897/CD
kcal/mol/NN
(/(
score/RB
,/,
-4.21/CD
)/)
./.
====================
The/DT
stereochemistry/NN
of/IN
the/DT
refined/VBN
model/NN
(/(
Procheck/NN
analysis/NN
)/)
(/(
Fig/NN
./.
====================
2A/NN
)/)
revealed/VBD
that/IN
99.2/CD
%/NN
of/IN
residues/NNS
were/VBD
situated/VBN
in/IN
the/DT
most/JJS
favorable/JJ
region/NN
and/CC
additional/JJ
allowed/VBD
regions/NNS
,/,
and/CC
0.8/CD
%/NN
(/(
Gln106/NN
)/)
of/IN
residues/NNS
were/VBD
in/IN
the/DT
generously/RB
allowed/VBD
region/NN
,/,
whereas/IN
none/NN
of/IN
the/DT
residues/NNS
fell/JJ
in/IN
the/DT
disallowed/JJ
region/NN
of/IN
the/DT
Ramachandran/NN
plot/NN
(/(
Fig/NN
./.
====================
2B/NN
)/)
./.
====================
ProSA-web/NN
evaluation/NN
revealed/VBD
a/DT
compatible/JJ
Z/NN
score/NN
(/(
Fig/NN
./.
====================
2C/NN
)/)
value/NN
of/IN
-4.34/CD
,/,
which/WDT
is/VBZ
well/RB
within/IN
the/DT
range/NN
of/IN
native/JJ
conformations/NNS
of/IN
crystal/JJ
structures/NNS
[/(
23/CD
]/)
./.
====================
The/DT
overall/JJ
residue/NN
energies/VBZ
of/IN
the/DT
E6/NN
3D/NN
model/NN
were/VBD
largely/RB
negative/JJ
except/IN
for/IN
one/CD
peak/NN
(/(
Fig/NN
./.
====================
2D/CD
)/)
./.
====================
The/DT
3D/NN
model/NN
of/IN
HPV-16/NN
E6/NN
protein/NN
showed/VBD
an/DT
LG/NN
score/RB
of/IN
2.531/CD
by/IN
Protein/NN
Quality/NN
Predictor/NN
(/(
ProQ/NN
)/)
tool/NN
,/,
implying/VBG
a/DT
high/JJ
accuracy/NN
level/NN
of/IN
the/DT
predicted/VBN
structure/NN
./.
====================
A/DT
ProQ/NN
LG/NN
score/RB
>/JJR
2.5/CD
is/VBZ
necessary/JJ
for/IN
suggesting/VBG
that/IN
a/DT
model/NN
is/VBZ
of/IN
very/RB
good/JJ
quality/NN
[/(
24/CD
]/)
./.
====================
Similar/JJ
assumptions/NNS
were/VBD
achieved/VBN
using/VBG
the/DT
ERRAT/NN
plot/NN
(/(
Fig/NN
./.
====================
2E/NN
)/)
,/,
where/WRB
the/DT
overall/JJ
quality/NN
factor/NN
was/VBD
91/CD
%/NN
./.
====================
All/DT
of/IN
these/DT
outcomes/NNS
recommended/VBN
the/DT
reliability/NN
of/IN
the/DT
proposed/JJ
model/NN
./.
====================
Docking/VBG
analysis/NN
of/IN
HPV-16/NN
E6/NN
with/IN
natural/JJ
ligands/NNS
====================
As/IN
all/DT
natural/JJ
ligands/NNS
(/(
inhibitors/NNS
)/)
were/VBD
found/VBN
to/TO
be/VB
docked/VBN
in/IN
various/JJ
conformations/NNS
and/CC
with/IN
varying/VBG
binding/NN
energies/VBZ
,/,
the/DT
lowest/JJS
energy/NN
conformation/NN
was/VBD
selected/VBN
./.
====================
Upon/IN
docking/NN
,/,
the/DT
high-ranked/JJ
binding/NN
energies/VBZ
of/IN
modeled/JJ
structures/NNS
of/IN
E6/NN
oncoprotein/NN
with/IN
natural/JJ
ligands/NNS
were/VBD
obtained/VBN
(/(
Table/JJ
1/CD
)/)
./.
====================
HPV/NN
E6/NN
degrades/NNS
the/DT
p53/NN
tumor/NN
suppressor/NN
protein/NN
./.
====================
To/TO
accomplish/VB
the/DT
process/NN
of/IN
degradation/NN
,/,
E6/NN
proteins/NNS
bind/VBP
and/CC
modify/VB
the/DT
target/NN
specificity/NN
of/IN
the/DT
ubiquitin/NN
ligase/NN
E6AP/NN
./.
====================
Based/VBN
on/IN
the/DT
resolved/JJ
structure/NN
of/IN
HPV-16/NN
E6/NN
by/IN
Zanier/NN
et/FW
al/JJ
./.
====================
[/(
29/CD
]/)
,/,
Cherry/NNP
et/FW
al/JJ
./.
====================
[/(
30/CD
]/)
revealed/VBD
in/IN
their/PRP$
docking/NN
analysis/NN
study/NN
that/IN
few/JJ
flavonoid/JJ
compounds/NNS
bind/VBP
in/IN
the/DT
hydrophobic/JJ
pocket/NN
of/IN
the/DT
E6/NN
and/CC
E6AP/NN
interface/NN
and/CC
mimic/JJ
the/DT
leucines/NNS
in/IN
the/DT
conserved/VBN
α-helical/JJ
motif/NN
of/IN
E6AP/NN
./.
====================
Another/DT
study/NN
also/RB
showed/VBD
that/IN
the/DT
biological/JJ
activities/NNS
of/IN
E6/NN
are/VBP
mediated/VBN
by/IN
the/DT
interaction/NN
of/IN
E6/NN
with/IN
the/DT
LXXLL/NN
motif/NN
of/IN
E6AP/NN
[/(
31/CD
]/)
./.
====================
In/IN
our/PRP$
study/NN
,/,
the/DT
E6/NN
protein/NN
of/IN
HPV-16/NN
showed/VBD
one/CD
LXXLL/NN
motif/NN
(/(
103LCDLL107/CD
)/)
./.
====================
Out/CC
of/IN
six/CD
natural/JJ
compounds/NNS
included/VBD
in/IN
our/PRP$
study/NN
,/,
three/CD
(/(
carrageenan/NN
,/,
EGCG/NN
,/,
and/CC
I3C/NN
)/)
were/VBD
found/VBN
to/TO
interact/VB
with/IN
the/DT
LXXLL/NN
motif/NN
of/IN
HPV-16/NN
E6/NN
by/IN
forming/VBG
a/DT
hydrogen/NN
bond/NN
with/IN
Leu106/NN
./.
====================
According/VBG
to/TO
Crook/NN
et/FW
al/JJ
./.
====================
[/(
32/CD
]/)
,/,
the/DT
p53-binding/NN
site/NN
is/VBZ
around/IN
amino/NN
acid/NN
residues/NNS
113-122/CD
(/(
CQKPLCPEEK/NN
)/)
of/IN
HPV-16/NN
E6/NN
protein/NN
./.
====================
The/DT
active/JJ
site/NN
of/IN
the/DT
model/NN
was/VBD
then/RB
analyzed/VBD
based/VBN
on/IN
the/DT
docking/NN
interaction/NN
of/IN
E6/NN
with/IN
the/DT
p53-binding/JJ
site/NN
with/IN
all/DT
6/CD
natural/JJ
ligands/NNS
./.
====================
Fig/NN
./.
====================
3/CD
shows/VBZ
a/DT
docked/JJ
pose/VBP
of/IN
six/CD
ligand/NN
molecules/NNS
with/IN
E6/NN
protein/NN
,/,
which/WDT
showed/VBD
almost/RB
similar/JJ
docking/NN
results/NNS
./.
====================
The/DT
detailed/JJ
interactions/NNS
are/VBP
given/VBN
in/IN
Table/JJ
1/CD
./.
====================
Each/DT
ligand/NN
interacts/VBZ
with/IN
the/DT
receptor/NN
at/IN
the/DT
p53-binding/NN
site/NN
./.
====================
Among/IN
the/DT
6/CD
different/JJ
ligands/NNS
,/,
carrageenan/NN
showed/VBD
the/DT
lowest/JJS
binding/NN
energy/NN
(/(
-13.95/CD
kcal/mol/NN
)/)
and/CC
inhibition/NN
constant/JJ
(/(
0.059/CD
µM/NN
)/)
for/IN
the/DT
protein-ligand/NN
complex/NN
./.
====================
Carrageenan/NN
was/VBD
found/VBN
to/TO
interact/VB
with/IN
the/DT
E6/NN
residues/NNS
Ala53/NN
,/,
Phe54/NN
,/,
Leu106/NN
,/,
Ile108/NN
,/,
Leu117/NN
,/,
and/CC
Lys122/NN
by/IN
forming/VBG
hydrogen/NN
bonds/NNS
./.
====================
As/IN
mentioned/VBN
in/IN
the/DT
introduction/NN
,/,
carrageenan/JJ
blocks/VBZ
HPV/NN
infection/NN
[/(
10/CD
]/)
;/:
from/IN
our/PRP$
docking/NN
study/NN
,/,
it/PRP
might/MD
be/VB
revealed/VBN
that/IN
the/DT
block/NN
of/IN
HPV/NN
infection/NN
might/MD
be/VB
due/JJ
the/DT
high/JJ
binding/NN
affinity/NN
of/IN
carrageenan/JJ
towards/IN
the/DT
p53-binding/JJ
site/NN
of/IN
E6/NN
protein/NN
./.
====================
WA/NN
showed/VBD
the/DT
second/JJ
lowest/JJS
binding/NN
energy/NN
of/IN
-7.58/CD
kcal/mol/NN
and/CC
an/DT
inhibition/NN
constant/JJ
of/IN
2.77/CD
µM/NN
./.
====================
During/IN
docking/NN
with/IN
the/DT
receptor/NN
hydrogen/NN
bond/NN
,/,
interactions/NNS
were/VBD
found/VBN
with/IN
three/CD
residues/NNS
(/(
Ala53/NN
,/,
Leu117/NNP
,/,
and/CC
Lys122/NN
)/)
of/IN
E6.The/DT
other/JJ
three/CD
compounds-EGCG/NN
,/,
I3C/NN
and/CC
jaceosidin-were/RB
also/RB
found/VBD
to/TO
interact/VB
with/IN
E6/NN
protein/NN
with/IN
binding/VBG
energies/VBZ
of/IN
-4.13/CD
,/,
-4.06/CD
,/,
and/CC
-4.01/CD
kcal/mol/NN
,/,
respectively/RB
./.
====================
Leu106/NN
,/,
Ile108/NN
,/,
and/CC
Leu117/NN
were/VBD
the/DT
interacting/VBG
residues/NNS
of/IN
the/DT
receptor/NN
proteins/NNS
with/IN
EGCG/NN
,/,
whereas/IN
I3C/NN
interacted/VBD
with/IN
Leu106/NN
,/,
Pro116/NN
,/,
and/CC
Lys122/NN
;/:
Jaceosidin/NN
interacted/VBD
with/IN
Phe54/NN
,/,
Pro116/NN
,/,
Leu117/NNP
,/,
and/CC
Lys122/NN
./.
====================
Curcumin/NN
was/VBD
found/VBN
to/TO
interact/VB
with/IN
E6/NN
protein/NN
with/IN
less/RBR
affinity/NN
(/(
binding/NN
energy/NN
of/IN
-3.09/CD
kcal/mol/NN
)/)
./.
====================
All/DT
natural/JJ
ligands/NNS
were/VBD
reported/VBN
to/TO
inhibit/VB
HPV/NN
infection/NN
;/:
our/PRP$
docking/NN
study/NN
also/RB
revealed/VBD
the/DT
in/FW
silico/NN
validation/NN
of/IN
the/DT
inhibition/NN
./.
====================
HPV-16/CD
is/VBZ
known/VBN
for/IN
causing/VBG
high-risk/VBP
cervical/JJ
cancer/NN
./.
====================
All/DT
ligands/NNS
were/VBD
found/VBN
to/TO
interact/VB
with/IN
E6/NN
oncoprotein/NN
of/IN
HPV-16/NN
with/IN
significant/JJ
binding/NN
energy/NN
and/CC
with/IN
amino/NN
acid/NN
residues/NNS
known/VBN
for/IN
p53/NN
binding/NN
./.
====================
This/DT
interaction/NN
might/MD
prevent/VB
E6/NN
protein/NN
from/IN
interacting/VBG
with/IN
host/NN
p53/NN
protein/NN
,/,
which/WDT
may/MD
correlate/VB
with/IN
why/WRB
these/DT
natural/JJ
compounds/NNS
are/VBP
used/VBN
to/TO
treat/VB
HPV/NN
infections/NNS
./.
====================
Conclusion/NN
====================
Different/JJ
natural/JJ
products/NNS
have/VBP
been/VBN
identified/VBN
and/CC
used/VBN
as/IN
promising/JJ
drug/NN
sources/NNS
against/IN
cancer/NN
caused/VBD
by/IN
HPV/NN
./.
====================
Advancement/JJ
in/IN
bioinformatics/NNS
and/CC
computational/JJ
biology/NN
are/VBP
proficient/JJ
invalidating/VBG
those/DT
natural/JJ
drugs/NNS
through/IN
in/IN
silico/NN
approaches/NNS
./.
====================
E6/CD
proteins/NNS
of/IN
high-risk/JJ
HPV/NN
16/CD
inactivate/VBP
p53/NN
by/IN
inducing/VBG
its/PRP$
degradation/NN
,/,
a/DT
process/NN
that/DT
requires/VBZ
a/DT
ternary/JJ
complex/NN
between/IN
E6/CD
,/,
E6AP/NN
,/,
and/CC
p53/NN
./.
====================
Low-risk/JJ
HPVs/NNS
,/,
such/JJ
as/IN
HPV-6/NN
and/CC
HPV-11/NN
,/,
do/VBP
not/RB
have/VB
the/DT
ability/NN
to/TO
degrade/VB
p53/NN
./.
====================
Thus/RB
,/,
E6/NN
of/IN
HPV-16/NN
is/VBZ
of/IN
considerable/JJ
interest/NN
for/IN
designing/VBG
novel/JJ
inhibitors/NNS
to/TO
overcome/VB
the/DT
challenges/NNS
of/IN
cervical/JJ
cancer/NN
./.
====================
A/DT
high-quality/JJ
3D/NN
model/NN
of/IN
E6/NN
obtained/VBN
through/IN
a/DT
computational/JJ
approach/NN
and/CC
docking/NN
analysis/NN
employing/VBG
AutoDock/NN
4.2/CD
in/IN
this/DT
study/NN
provided/VBD
high-throughput/JJ
validation/NN
./.
====================
This/DT
in/IN
silico/NN
approach/NN
may/MD
be/VB
of/IN
interest/NN
in/IN
designing/VBG
new/JJ
drugs/NNS
from/IN
natural/JJ
sources/NNS
against/IN
cervical/JJ
cancer/NN
./.
====================
Natural/JJ
compounds/NNS
reported/VBD
to/TO
use/VB
against/IN
human/JJ
papillomavirus/NN
infection/NN
./.
====================
(/(
A/NN
)/)
3D/NN
structure/NN
of/IN
predicted/VBN
human/JJ
papillomavirus/NN
16/CD
(/(
HPV-16/NN
)/)
E6/NN
model/NN
./.
====================
(/(
B/NN
)/)
Ramachandran/NN
plot/NN
of/IN
predicted/VBN
E6/NN
model/NN
(/(
the/DT
red/JJ
,/,
dark/VBP
yellow/RB
,/,
and/CC
light/JJ
yellow/RB
regions/NNS
represent/VBP
the/DT
most/JJS
favored/VBD
,/,
allowed/VBD
,/,
and/CC
generously/RB
allowed/VBD
regions/NNS
)/)
./.
====================
(/(
C/NN
)/)
ProSA-web/NN
Z-scores/NNS
of/IN
all/DT
protein/NN
chains/NNS
in/IN
PDB/NN
determined/VBN
by/IN
X-ray/NN
crystallography/NN
(/(
light/NN
blue/JJ
)/)
and/CC
nuclear/JJ
magnetic/JJ
resonance/NN
spectroscopy/NN
with/IN
respect/NN
to/TO
their/PRP$
length/NN
./.
====================
The/DT
Z-score/JJ
of/IN
E6/NN
was/VBD
present/JJ
in/IN
the/DT
range/NN
represented/VBN
in/IN
black/JJ
dot/JJ
(/(
D/NN
)/)
Energy/NN
plot/NN
for/IN
the/DT
predicted/VBN
E6/NN
of/IN
HPV-16/NN
./.
====================
(/(
E/NN
)/)
ERRAT/NN
plot/NN
for/IN
residue-wise/JJ
analysis/NN
of/IN
homology/NN
model/NN
./.
====================
Interaction/NN
profile/NN
of/IN
E6/NN
with/IN
natural/JJ
ligands/NNS
carrageenan/JJ
(/(
A/DT
)/)
,/,
withaferin/IN
A/DT
(/(
B/NN
)/)
,/,
epigallocatechin/NN
gallate/NN
(/(
C/NN
)/)
,/,
indole-3-carbinol/NNP
(/(
D/NN
)/)
,/,
jaceosidin/NN
(/(
E/NN
)/)
,/,
and/CC
curcumin/NN
(/(
F/NN
)/)
showing/VBG
interaction/NN
of/IN
ligands/NNS
with/IN
active/JJ
site/NN
residues/NNS
of/IN
E6/NN
by/IN
forming/VBG
hydrogen/NN
bonds/NNS
,/,
shown/VBN
in/IN
dotted/JJ
lines/NNS
./.
====================
Polar/JJ
contact/NN
information/NN
from/IN
docking/NN
calculations/NNS
between/IN
ligands/NNS
and/CC
protein/NN
====================
